Dapagliflozin vs Ertugliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline

Dapagliflozin · Farxiga / Forxiga

Marketed by AstraZeneca and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00528372 · Phase 3 · completed

The study was randomized, double-blind, placebo-controlled, and included 1,067 enrolled participants, with 558 receiving short-term treatment; its primary HbA1c endpoint is an accepted disease-defining measure for type 2 diabetes. Results were mixed across the primary dose comparisons: 5 mg and 10 mg morning doses significantly outperformed placebo, while 2.5 mg did not, and the exploratory high-baseline-HbA1c group lacked a comparator.

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02) (met)

Result source: NCT01392677

Ertugliflozin · Steglatro

Marketed by Merck & Co. and partners

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT01986881 · Phase 3 · completed

This trial was randomized, double-blind, and placebo-controlled with over 8,000 participants, giving it strong statistical power, and its primary endpoint was a hard clinical composite (cardiovascular death, non-fatal MI, or non-fatal stroke) rather than a lab surrogate. The trial was designed as a cardiovascular-safety non-inferiority study, and the pre-specified margin was met, with the ertugliflozin-placebo hazard ratio's upper confidence bound (1.114) falling below the 1.3 non-inferiority threshold, demonstrating that ertugliflozin does not increase cardiovascular risk versus placebo in this population.

Next expected readout: January 2028 · NCT07621380 (registry estimate)

Reported efficacy

Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years); Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study) (Baseline and Week 18): Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years (met)

Result source: NCT01986881

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDapagliflozinErtugliflozin
HbA1c, change-0.9% vs -0.2%−0.7 vs placebo10 mg AM · wk 24 · n 65NCT00528372
50 other results
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 73 · Phase 3 · primary NCT00528372
  • -0.9% vs -0.2% 10 mg · wk 24 · n 108 · Phase 3 · primary NCT01392677
  • -0.9% vs -0.3% 10mg · wk 24 · n 192 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 5mg · wk 24 · n 210 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 2.5mg · wk 24 · n 198 · Phase 3 · primary NCT00673231
  • -0.6% vs 0.1% 10 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.7% vs 0.1% 20 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.8% vs -0.2% 5 mg AM · wk 24 · n 61 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 63 · Phase 3 · primary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 64 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 62 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.3% 10 mg · wk 24 · n 132 · Phase 3 · primary NCT00528879
  • -0.8% vs -0.1% 10 mg · wk 24 · n 150 · Phase 3 · primary NCT00680745
  • -1.0% vs -0.4% 10MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 5 mg · wk 24 · n 133 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 5 mg · wk 24 · n 142 · Phase 3 · primary NCT00680745
  • -0.8% vs -0.4% 5MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 135 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 2.5 mg · wk 24 · n 154 · Phase 3 · primary NCT00680745
  • -0.6% vs 0.4% wk 26 · n 75 · Phase 3 · primary NCT03199053
  • -0.5% vs 0.0% wk 24 · n 223 · Phase 3 · primary NCT00984867
  • -1.2% vs -1.4% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT00643851
  • -2.0% vs -1.4% wk 24 · n 185 · Phase 3 · primary NCT00643851
  • -0.5% vs -0.5% wk 52 · n 400 · Phase 3 · primary NCT00660907
  • -2.0% vs -1.4% wk 24 · n 202 · Phase 3 · primary NCT00859898
  • -1.4% vs -1.4% wk 24 · n 216 · Phase 3 · primary NCT00859898
  • -0.9% vs -0.2% 10 mg AM · wk 24 · n 59 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 60 · Phase 3 · secondary NCT00528372
  • -0.7% vs -0.2% 5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 48 · Phase 3 · secondary NCT00528372
  • -0.9% vs -0.3% 10 mg · wk 24 · n 104 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 118 · Phase 3 · secondary NCT00528879
  • -2.0% vs 0.2% 10 mg AM · wk 24 · n 14 · Phase 3 · secondary NCT00528372
  • -1.2% vs 0.2% 10 mg PM · wk 24 · n 12 · Phase 3 · secondary NCT00528372
  • -1.4% vs -0.5% 5 mg · wk 24 · n 34 · Phase 3 · secondary NCT00528879
  • -0.8% vs 0.0% wk 24 · n 94 · Phase 3 · secondary NCT00984867
  • -2% vs 0.2% 5 mg AM · wk 24 · n 9 · Phase 3 · secondary NCT00528372
  • -1.5% vs 0.2% 5 mg PM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.3% vs 0.2% 2.5 mg AM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.4% vs 0.2% 2.5 mg PM · wk 24 · n 11 · Phase 3 · secondary NCT00528372
  • -1.3% vs -0.5% 10 mg · wk 24 · n 18 · Phase 3 · secondary NCT00528879
  • -1.2% vs -0.5% 2.5 mg · wk 24 · n 17 · Phase 3 · secondary NCT00528879
  • -1.7% vs -1.8% 5 mg · wk 24 · n 96 · Phase 3 · secondary NCT00643851
  • -3.0% vs -1.8% wk 24 · n 92 · Phase 3 · secondary NCT00643851
  • -2.6% vs -2.0% wk 24 · n 106 · Phase 3 · secondary NCT00859898
  • -2.1% vs -2.0% wk 24 · n 97 · Phase 3 · secondary NCT00859898
  • -1% vs -0.5% wk 52 · n 56 · Phase 4 · secondary NCT02564926
-1.0% vs 0.2%−1.2 vs placebo15 mg · wk 26 · n 151NCT01958671
65 other results
  • -0.9% vs -0.0% 15 mg · wk 26 · n 205 · Phase 3 · primary NCT02033889
  • -0.9% vs -0.1% 15 mg · wk 26 · n 153 · Phase 3 · primary NCT02036515
  • -0.4% vs -0.3% 15 mg · wk 26 · n 155 · Phase 3 · primary NCT01986855
  • -0.9% vs -0.2% 15 mg · wk 26 · n 169 · Phase 3 · primary NCT02630706
  • -0.8% vs -0.2% 15 mg · wk 18 · n 370 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.2% 5 mg · wk 18 · n 348 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.6% 15 mg · wk 18 · n 54 · Phase 3 · primary NCT01986881
  • -1.0% vs -0.2% 15 mg · wk 18 · n 113 · Phase 3 · primary NCT01986881
  • -0.8% vs 0.2% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT01958671
  • -0.7% vs -0.0% 5 mg · wk 26 · n 207 · Phase 3 · primary NCT02033889
  • -0.8% vs -0.1% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT02036515
  • -0.3% vs -0.3% 5 mg · wk 26 · n 158 · Phase 3 · primary NCT01986855
  • -1% vs -0.2% 5 mg · wk 26 · n 170 · Phase 3 · primary NCT02630706
  • -0.9% vs -0.6% 5 mg · wk 18 · n 55 · Phase 3 · primary NCT01986881
  • -0.9% vs -0.2% 5 mg · wk 18 · n 100 · Phase 3 · primary NCT01986881
  • -1.7% vs -0.4% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · primary NCT02226003
  • -1.6% vs -0.4% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · primary NCT02226003
  • -0.6% vs 0.1% wk 24 · n 111 · Phase 3 · primary NCT04029480
  • -0.6% vs -0.7% 15 mg · wk 52 · n 440 · Phase 3 · primary NCT01999218
  • -1.1% vs -1.1% 15 mg · wk 26 · n 248 · Phase 3 · primary NCT02099110
  • -0.6% vs -0.7% 5 mg · wk 52 · n 448 · Phase 3 · primary NCT01999218
  • -1.0% vs -1.1% 5 mg · wk 26 · n 250 · Phase 3 · primary NCT02099110
  • -1.5% vs -1.1% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · primary NCT02099110
  • -1.5% vs -1.1% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · primary NCT02099110
  • -0.7% vs -0.2% 15 mg · wk 52 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 15 mg · wk 18 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.5% vs -0.1% 15 mg · wk 104 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 15 mg · wk 156 · n 1574 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 15 mg · wk 208 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -0.5% vs -0.1% 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 5 mg · wk 156 · n 1590 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.3% vs -0.1% 15 mg · wk 260 · n 527 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.7% 5 mg · wk 52 · n 179 · Phase 3 · secondary NCT02033889
  • -0.3% vs -0.1% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -1.0% vs -0.7% 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -0.8% vs 0.0% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -0.4% vs -0.3% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -0.9% vs -0.6% 15 mg · wk 104 · n 142 · Phase 3 · secondary NCT02033889
  • -0.8% vs 0.0% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -0.3% vs -0.3% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -0.5% vs 0.3% 5 mg · wk 24 · n 85 · Phase 3 · secondary NCT04029480
  • -0.6% vs -0.6% 5 mg · wk 104 · n 147 · Phase 3 · secondary NCT02033889
  • -0.2% vs 0.8% wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -0.4% vs 0.3% wk 24 · n 89 · Phase 3 · secondary NCT04029480
  • -0.1% vs 0.2% 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.3% vs 0.2% 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -0.8% vs -0.1% 5 mg · wk 12 · n 53 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 12 · n 50 · Phase 2 · primary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 12 · n 51 · Phase 2 · primary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 12 · n 54 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -0.3% vs 0% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.1% vs 0% 1 mg · wk 2 · n 52 · Phase 2 · secondary NCT01059825
Body weight, change (kg)-3.2 vs -2.2−1 vs placebo10 mg AM · wk 24 · n 69NCT00528372
40 other results
  • -3.0 vs -2.2 10 mg PM · wk 24 · n 74 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg AM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg PM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • -2.6 vs -0.6 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.7 vs 0.0 10mg · wk 24 · n 192 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 5mg · wk 24 · n 210 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 2.5mg · wk 24 · n 198 · Phase 3 · secondary NCT00673231
  • -2.8 vs -2.2 5 mg AM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • -3.5 vs -2.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -2.9 vs -2.4 5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -3.7 vs -2.4 5 mg PM · wk 24 · n 57 · Phase 3 · secondary NCT00528372
  • -3.3 vs -2.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -3.8 vs -2.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 2.5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -4.3 vs -2.4 2.5 mg PM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -2.9 vs -0.9 10 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • -3.1 vs -1.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT00528879
  • -2.3 vs -0.7 10 mg · wk 24 · n 151 · Phase 3 · secondary NCT00680745
  • -2.5 vs -0.8 10 mg · wk 24 · n 99 · Phase 3 · secondary NCT00680745
  • -0.1 vs 1.6 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.1 vs 1.8 10MG · wk 24 · n 113 · Phase 3 · secondary NCT00683878
  • -3.0 vs -0.9 5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -3.2 vs -1.0 5 mg · wk 24 · n 111 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.7 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.7 vs -0.8 5 mg · wk 24 · n 97 · Phase 3 · secondary NCT00680745
  • 0.1 vs 1.6 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 0.3 vs 1.8 5MG · wk 24 · n 101 · Phase 3 · secondary NCT00683878
  • -2.2 vs -0.9 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -2.4 vs -1.0 2.5 mg · wk 24 · n 120 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.7 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -1.2 vs -0.8 2.5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00680745
  • -2.1 vs -0.3 wk 24 · n 223 · Phase 3 · secondary NCT00984867
  • -2.6 vs -1.3 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -2.9 vs -1.5 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT00643851
  • -2.7 vs -1.3 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.0 vs -1.5 wk 24 · n 142 · Phase 3 · secondary NCT00643851
  • -3.2 vs 1.4 wk 52 · n 400 · Phase 3 · secondary NCT00660907
  • -3.3 vs -1.4 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.7 vs -1.4 wk 24 · n 219 · Phase 3 · secondary NCT00859898
  • -2.4 vs 1.3 wk 52 · n 56 · Phase 4 · secondary NCT02564926
-2.8 vs -0.4−2.4 vs placebo15 mg · wk 52 · n 2746NCT01986881
43 other results
  • -2.3 vs -0.4 15 mg · wk 18 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.2 vs -0.7 15 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.4 vs -1.0 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • -3.8 vs -1.3 15 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.5 vs -0.4 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.4 5 mg · wk 18 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.7 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.0 vs -1.0 5 mg · wk 156 · n 1595 · Phase 3 · secondary NCT01986881
  • -3.4 vs -1.3 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.4 vs 0.1 15 mg · wk 52 · n 178 · Phase 3 · secondary NCT02033889
  • -3.6 vs -1.4 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -2.9 vs -1.3 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -3.2 vs -1.2 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -2.1 vs -0.3 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -4.6 vs -1.2 15 mg · wk 260 · n 530 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.9 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -3.2 vs 0.1 5 mg · wk 52 · n 181 · Phase 3 · secondary NCT02033889
  • -1.9 vs -0.3 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -3.7 vs -1.2 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -3.0 vs -1.3 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -1.4 vs 0.5 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -3.0 vs -1.2 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.2 vs -0.7 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.4 vs -0.5 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -3.6 vs -0.2 15 mg · wk 104 · n 145 · Phase 3 · secondary NCT02033889
  • -3.5 vs -0.9 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -3.2 vs -1.4 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • -3.0 vs -1.3 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -3.4 vs -1.3 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -1.3 vs 0.5 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -1.8 vs -0.7 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.5 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -3.8 vs -0.2 5 mg · wk 104 · n 148 · Phase 3 · secondary NCT02033889
  • -3.0 vs -0.9 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • -2.9 vs -0.9 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • -7.4 vs -1.0 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -4.2 vs -1.0 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -3.4 vs 0.9 15 mg · wk 52 · n 440 · Phase 3 · secondary NCT01999218
  • -3.7 vs -0.7 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -3.0 vs 0.9 5 mg · wk 52 · n 448 · Phase 3 · secondary NCT01999218
  • -2.7 vs -0.7 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -2.9 vs -0.7 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.5 vs -0.7 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
HbA1c below 7%50.8% vs 31.6%+19.2 vs placebo10 mg AM · wk 24 · n 65NCT00528372
17 other results
  • 51.6% vs 31.6% 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • 31.8% vs 11.1% 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • 44.2% vs 31.6% 5 mg AM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • 44% vs 31.6% 5 mg PM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • 41.3% vs 31.6% 2.5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • 51.4% vs 31.6% 2.5 mg PM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • 40.6% vs 25.9% 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • 31.7% vs 13% 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • 38.8% vs 22.4% 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 37.5% vs 25.9% 5 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • 30.3% vs 13% 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • 32.5% vs 22.4% 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 33% vs 25.9% 2.5 mg · wk 24 · n 135 · Phase 3 · secondary NCT00528879
  • 26.8% vs 13% 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • 26.6% vs 10% wk 26 · n 64 · Phase 3 · secondary NCT03199053
  • 22.5% vs 34.6% 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT00643851
  • 52.4% vs 34.6% wk 24 · n 185 · Phase 3 · secondary NCT00643851
28.2% vs 15.5%+12.7 vs placebo15 mg · wk 18 · n 2520NCT01986881
43 other results
  • 29% vs 17.4% 15 mg · wk 52 · n 2347 · Phase 3 · secondary NCT01986881
  • 23.8% vs 16.6% 15 mg · wk 104 · n 1541 · Phase 3 · secondary NCT01986881
  • 22.7% vs 16.9% 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • 22.7% vs 18.2% 15 mg · wk 208 · n 860 · Phase 3 · secondary NCT01986881
  • 28.4% vs 15.5% 5 mg · wk 18 · n 2544 · Phase 3 · secondary NCT01986881
  • 28.3% vs 17.4% 5 mg · wk 52 · n 2363 · Phase 3 · secondary NCT01986881
  • 23.9% vs 16.6% 5 mg · wk 104 · n 1570 · Phase 3 · secondary NCT01986881
  • 23.1% vs 16.9% 5 mg · wk 156 · n 1592 · Phase 3 · secondary NCT01986881
  • 35.8% vs 13.1% 15 mg · wk 26 · n 151 · Phase 3 · secondary NCT01958671
  • 40% vs 15.8% 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • 40.8% vs 16.2% 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • 21.1% vs 10.7% 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • 33.7% vs 19.1% 15 mg · wk 104 · n 205 · Phase 3 · secondary NCT02033889
  • 20% vs 16.5% 15 mg · wk 260 · n 529 · Phase 3 · secondary NCT01986881
  • 20.7% vs 10.7% 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • 24.9% vs 18.2% 5 mg · wk 208 · n 876 · Phase 3 · secondary NCT01986881
  • 39.9% vs 17% 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • 11.3% vs 12.1% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • 36.6% vs 30.6% 15 mg · wk 52 · n 205 · Phase 3 · secondary NCT02033889
  • 35.3% vs 15.8% 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • 34.8% vs 30.6% 5 mg · wk 52 · n 207 · Phase 3 · secondary NCT02033889
  • 24.6% vs 19.1% 5 mg · wk 104 · n 207 · Phase 3 · secondary NCT02033889
  • 18.6% vs 16.5% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • 27.8% vs 25% 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • 32.7% vs 12.8% 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • 32.7% vs 13.7% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • 28.2% vs 13.1% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • 32.1% vs 17% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • 16.2% vs 12.1% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • 38.2% vs 16.2% 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • 32.7% vs 25% 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • 37% vs 12.8% 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • 33.3% vs 13.7% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • 31.3% vs 8.3% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • 35.7% vs 8.3% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • 31.9% vs 32.8% 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • 26.4% vs 32.8% 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • 49.2% vs 32.8% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • 52.3% vs 32.8% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • 42.9% vs 15.6% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT01059825
  • 36.2% vs 15.6% 25 mg · wk 12 · n 47 · Phase 2 · secondary NCT01059825
  • 38.6% vs 15.6% 10 mg · wk 12 · n 44 · Phase 2 · secondary NCT01059825
  • 44% vs 15.6% 1 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825
Fasting plasma glucose, change-1.3 vs 0.2−1.5 vs placebowk 24 · n 222NCT00984867
34 other results
  • -1.6 vs -0.2 10 mg AM · wk 24 · n 70 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.2 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • -1.9 vs -0.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.2 vs 0.2 10mg · wk 24 · n 183 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.2 5mg · wk 24 · n 204 · Phase 3 · secondary NCT00673231
  • 0.1 vs 1.0 10 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -0.9 vs -0.1 10 mg AM · wk 1 · n 65 · Phase 3 · secondary NCT00528372
  • -0.7 vs 0.2 2.5mg · wk 24 · n 190 · Phase 3 · secondary NCT00673231
  • -1.1 vs -0.1 10 mg PM · wk 1 · n 60 · Phase 3 · secondary NCT00528372
  • -0.5 vs 1.0 20 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -1.3 vs -0.2 5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • -1.5 vs -0.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -0.9 vs -0.1 5 mg AM · wk 1 · n 56 · Phase 3 · secondary NCT00528372
  • -1.0 vs -0.1 5 mg PM · wk 1 · n 54 · Phase 3 · secondary NCT00528372
  • -0.8 vs -0.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -1.4 vs -0.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -0.2 vs -0.1 2.5 mg AM · wk 1 · n 57 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.1 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • -0.8 vs -0.1 2.5 mg PM · wk 1 · n 48 · Phase 3 · secondary NCT00528372
  • -1.3 vs -0.3 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.3 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.9 vs 0.1 10 mg · wk 1 · n 115 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.3 5 mg · wk 24 · n 136 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.1 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.4 vs -0.3 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.7 vs 0.1 5 mg · wk 1 · n 121 · Phase 3 · secondary NCT00528879
  • -1.0 vs -0.3 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -0.9 vs -0.1 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -0.3 vs 0.1 2.5 mg · wk 1 · n 120 · Phase 3 · secondary NCT00528879
  • -0.6 vs 0.5 wk 26 · n 75 · Phase 3 · secondary NCT03199053
  • -2.3 vs -1.9 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.6 vs -1.9 wk 24 · n 216 · Phase 3 · secondary NCT00859898
-1.9 vs -0.9−1 vs placebo15 mg · wk 18 · n 2747NCT01986881
63 other results
  • -1.6 vs -0.5 15 mg · wk 52 · n 2328 · Phase 3 · secondary NCT01986881
  • -1.4 vs -0.2 15 mg · wk 104 · n 1536 · Phase 3 · secondary NCT01986881
  • -1.3 vs -0.2 15 mg · wk 156 · n 1567 · Phase 3 · secondary NCT01986881
  • -1.8 vs -0.9 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -0.9 vs 0.2 15 mg · wk 208 · n 861 · Phase 3 · secondary NCT01986881
  • -1.6 vs -0.5 5 mg · wk 52 · n 2352 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.2 5 mg · wk 104 · n 1562 · Phase 3 · secondary NCT01986881
  • -1.1 vs -0.2 5 mg · wk 156 · n 1579 · Phase 3 · secondary NCT01986881
  • -2.2 vs -0.1 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -1.8 vs -0.4 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -0.6 vs -0.3 15 mg · wk 260 · n 524 · Phase 3 · secondary NCT01986881
  • -1.8 vs -0.1 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -1.9 vs -0.7 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.6 vs -0.6 15 mg · wk 104 · n 144 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.1 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.4 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -0.8 vs 0.2 5 mg · wk 208 · n 868 · Phase 3 · secondary NCT01986881
  • -0.8 vs -0.3 5 mg · wk 260 · n 520 · Phase 3 · secondary NCT01986881
  • -2.4 vs 0.0 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -1.1 vs -0.3 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -1.9 vs -0.4 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -1.5 vs -0.8 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -1.5 vs 0.2 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -1.9 vs 0.0 5 mg · wk 26 · n 155 · Phase 3 · secondary NCT01958671
  • -1.5 vs -0.1 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -0.7 vs -0.3 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -2.1 vs -0.4 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.6 vs -0.8 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.7 5 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.4 vs 0.2 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -1.0 vs -0.6 5 mg · wk 104 · n 143 · Phase 3 · secondary NCT02033889
  • -1.1 vs 0.5 wk 24 · n 111 · Phase 3 · secondary NCT04029480
  • -0.7 vs 1.2 wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -4.7 vs 0.8 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.1 vs 0.8 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -2.0 vs -1.4 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -2.0 vs -1.4 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -2.7 vs -1.4 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.4 vs -1.4 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • -1.3 vs 0.1 5 mg · wk 12 · n 53 · Phase 2 · secondary NCT01059825
  • -1.4 vs 0.2 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 5 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.3 vs 0.3 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -1.3 vs -0.3 5 mg · wk 2 · n 34 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.1 25 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.5 vs 0.3 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -1.8 vs -0.3 25 mg · wk 2 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.1 10 mg · wk 12 · n 51 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.2 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.3 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -1.5 vs 0.3 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.1 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.2 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.8 vs 0.2 1 mg · wk 4 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.6 vs -0.3 1 mg · wk 2 · n 35 · Phase 2 · secondary NCT01096667
  • -0.8 vs 0.3 1 mg · wk 2 · n 51 · Phase 2 · secondary NCT01059825
3-point MACE (% with event)—Not posted · NCT04170998—Not posted · NCT03717194

HbA1c, change

Dapagliflozin
-0.9% vs -0.2%−0.7 vs placebo10 mg AM · wk 24 · n 65NCT00528372
50 other results
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 73 · Phase 3 · primary NCT00528372
  • -0.9% vs -0.2% 10 mg · wk 24 · n 108 · Phase 3 · primary NCT01392677
  • -0.9% vs -0.3% 10mg · wk 24 · n 192 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 5mg · wk 24 · n 210 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 2.5mg · wk 24 · n 198 · Phase 3 · primary NCT00673231
  • -0.6% vs 0.1% 10 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.7% vs 0.1% 20 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.8% vs -0.2% 5 mg AM · wk 24 · n 61 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 63 · Phase 3 · primary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 64 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 62 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.3% 10 mg · wk 24 · n 132 · Phase 3 · primary NCT00528879
  • -0.8% vs -0.1% 10 mg · wk 24 · n 150 · Phase 3 · primary NCT00680745
  • -1.0% vs -0.4% 10MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 5 mg · wk 24 · n 133 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 5 mg · wk 24 · n 142 · Phase 3 · primary NCT00680745
  • -0.8% vs -0.4% 5MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 135 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 2.5 mg · wk 24 · n 154 · Phase 3 · primary NCT00680745
  • -0.6% vs 0.4% wk 26 · n 75 · Phase 3 · primary NCT03199053
  • -0.5% vs 0.0% wk 24 · n 223 · Phase 3 · primary NCT00984867
  • -1.2% vs -1.4% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT00643851
  • -2.0% vs -1.4% wk 24 · n 185 · Phase 3 · primary NCT00643851
  • -0.5% vs -0.5% wk 52 · n 400 · Phase 3 · primary NCT00660907
  • -2.0% vs -1.4% wk 24 · n 202 · Phase 3 · primary NCT00859898
  • -1.4% vs -1.4% wk 24 · n 216 · Phase 3 · primary NCT00859898
  • -0.9% vs -0.2% 10 mg AM · wk 24 · n 59 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 60 · Phase 3 · secondary NCT00528372
  • -0.7% vs -0.2% 5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 48 · Phase 3 · secondary NCT00528372
  • -0.9% vs -0.3% 10 mg · wk 24 · n 104 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 118 · Phase 3 · secondary NCT00528879
  • -2.0% vs 0.2% 10 mg AM · wk 24 · n 14 · Phase 3 · secondary NCT00528372
  • -1.2% vs 0.2% 10 mg PM · wk 24 · n 12 · Phase 3 · secondary NCT00528372
  • -1.4% vs -0.5% 5 mg · wk 24 · n 34 · Phase 3 · secondary NCT00528879
  • -0.8% vs 0.0% wk 24 · n 94 · Phase 3 · secondary NCT00984867
  • -2% vs 0.2% 5 mg AM · wk 24 · n 9 · Phase 3 · secondary NCT00528372
  • -1.5% vs 0.2% 5 mg PM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.3% vs 0.2% 2.5 mg AM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.4% vs 0.2% 2.5 mg PM · wk 24 · n 11 · Phase 3 · secondary NCT00528372
  • -1.3% vs -0.5% 10 mg · wk 24 · n 18 · Phase 3 · secondary NCT00528879
  • -1.2% vs -0.5% 2.5 mg · wk 24 · n 17 · Phase 3 · secondary NCT00528879
  • -1.7% vs -1.8% 5 mg · wk 24 · n 96 · Phase 3 · secondary NCT00643851
  • -3.0% vs -1.8% wk 24 · n 92 · Phase 3 · secondary NCT00643851
  • -2.6% vs -2.0% wk 24 · n 106 · Phase 3 · secondary NCT00859898
  • -2.1% vs -2.0% wk 24 · n 97 · Phase 3 · secondary NCT00859898
  • -1% vs -0.5% wk 52 · n 56 · Phase 4 · secondary NCT02564926
Ertugliflozin
-1.0% vs 0.2%−1.2 vs placebo15 mg · wk 26 · n 151NCT01958671
65 other results
  • -0.9% vs -0.0% 15 mg · wk 26 · n 205 · Phase 3 · primary NCT02033889
  • -0.9% vs -0.1% 15 mg · wk 26 · n 153 · Phase 3 · primary NCT02036515
  • -0.4% vs -0.3% 15 mg · wk 26 · n 155 · Phase 3 · primary NCT01986855
  • -0.9% vs -0.2% 15 mg · wk 26 · n 169 · Phase 3 · primary NCT02630706
  • -0.8% vs -0.2% 15 mg · wk 18 · n 370 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.2% 5 mg · wk 18 · n 348 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.6% 15 mg · wk 18 · n 54 · Phase 3 · primary NCT01986881
  • -1.0% vs -0.2% 15 mg · wk 18 · n 113 · Phase 3 · primary NCT01986881
  • -0.8% vs 0.2% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT01958671
  • -0.7% vs -0.0% 5 mg · wk 26 · n 207 · Phase 3 · primary NCT02033889
  • -0.8% vs -0.1% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT02036515
  • -0.3% vs -0.3% 5 mg · wk 26 · n 158 · Phase 3 · primary NCT01986855
  • -1% vs -0.2% 5 mg · wk 26 · n 170 · Phase 3 · primary NCT02630706
  • -0.9% vs -0.6% 5 mg · wk 18 · n 55 · Phase 3 · primary NCT01986881
  • -0.9% vs -0.2% 5 mg · wk 18 · n 100 · Phase 3 · primary NCT01986881
  • -1.7% vs -0.4% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · primary NCT02226003
  • -1.6% vs -0.4% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · primary NCT02226003
  • -0.6% vs 0.1% wk 24 · n 111 · Phase 3 · primary NCT04029480
  • -0.6% vs -0.7% 15 mg · wk 52 · n 440 · Phase 3 · primary NCT01999218
  • -1.1% vs -1.1% 15 mg · wk 26 · n 248 · Phase 3 · primary NCT02099110
  • -0.6% vs -0.7% 5 mg · wk 52 · n 448 · Phase 3 · primary NCT01999218
  • -1.0% vs -1.1% 5 mg · wk 26 · n 250 · Phase 3 · primary NCT02099110
  • -1.5% vs -1.1% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · primary NCT02099110
  • -1.5% vs -1.1% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · primary NCT02099110
  • -0.7% vs -0.2% 15 mg · wk 52 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 15 mg · wk 18 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.5% vs -0.1% 15 mg · wk 104 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 15 mg · wk 156 · n 1574 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 15 mg · wk 208 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -0.5% vs -0.1% 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 5 mg · wk 156 · n 1590 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.3% vs -0.1% 15 mg · wk 260 · n 527 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.7% 5 mg · wk 52 · n 179 · Phase 3 · secondary NCT02033889
  • -0.3% vs -0.1% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -1.0% vs -0.7% 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -0.8% vs 0.0% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -0.4% vs -0.3% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -0.9% vs -0.6% 15 mg · wk 104 · n 142 · Phase 3 · secondary NCT02033889
  • -0.8% vs 0.0% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -0.3% vs -0.3% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -0.5% vs 0.3% 5 mg · wk 24 · n 85 · Phase 3 · secondary NCT04029480
  • -0.6% vs -0.6% 5 mg · wk 104 · n 147 · Phase 3 · secondary NCT02033889
  • -0.2% vs 0.8% wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -0.4% vs 0.3% wk 24 · n 89 · Phase 3 · secondary NCT04029480
  • -0.1% vs 0.2% 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.3% vs 0.2% 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -0.8% vs -0.1% 5 mg · wk 12 · n 53 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 12 · n 50 · Phase 2 · primary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 12 · n 51 · Phase 2 · primary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 12 · n 54 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -0.3% vs 0% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.1% vs 0% 1 mg · wk 2 · n 52 · Phase 2 · secondary NCT01059825

Body weight, change (kg)

Dapagliflozin
-3.2 vs -2.2−1 vs placebo10 mg AM · wk 24 · n 69NCT00528372
40 other results
  • -3.0 vs -2.2 10 mg PM · wk 24 · n 74 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg AM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg PM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • -2.6 vs -0.6 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.7 vs 0.0 10mg · wk 24 · n 192 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 5mg · wk 24 · n 210 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 2.5mg · wk 24 · n 198 · Phase 3 · secondary NCT00673231
  • -2.8 vs -2.2 5 mg AM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • -3.5 vs -2.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -2.9 vs -2.4 5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -3.7 vs -2.4 5 mg PM · wk 24 · n 57 · Phase 3 · secondary NCT00528372
  • -3.3 vs -2.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -3.8 vs -2.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 2.5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -4.3 vs -2.4 2.5 mg PM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -2.9 vs -0.9 10 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • -3.1 vs -1.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT00528879
  • -2.3 vs -0.7 10 mg · wk 24 · n 151 · Phase 3 · secondary NCT00680745
  • -2.5 vs -0.8 10 mg · wk 24 · n 99 · Phase 3 · secondary NCT00680745
  • -0.1 vs 1.6 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.1 vs 1.8 10MG · wk 24 · n 113 · Phase 3 · secondary NCT00683878
  • -3.0 vs -0.9 5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -3.2 vs -1.0 5 mg · wk 24 · n 111 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.7 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.7 vs -0.8 5 mg · wk 24 · n 97 · Phase 3 · secondary NCT00680745
  • 0.1 vs 1.6 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 0.3 vs 1.8 5MG · wk 24 · n 101 · Phase 3 · secondary NCT00683878
  • -2.2 vs -0.9 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -2.4 vs -1.0 2.5 mg · wk 24 · n 120 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.7 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -1.2 vs -0.8 2.5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00680745
  • -2.1 vs -0.3 wk 24 · n 223 · Phase 3 · secondary NCT00984867
  • -2.6 vs -1.3 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -2.9 vs -1.5 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT00643851
  • -2.7 vs -1.3 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.0 vs -1.5 wk 24 · n 142 · Phase 3 · secondary NCT00643851
  • -3.2 vs 1.4 wk 52 · n 400 · Phase 3 · secondary NCT00660907
  • -3.3 vs -1.4 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.7 vs -1.4 wk 24 · n 219 · Phase 3 · secondary NCT00859898
  • -2.4 vs 1.3 wk 52 · n 56 · Phase 4 · secondary NCT02564926
Ertugliflozin
-2.8 vs -0.4−2.4 vs placebo15 mg · wk 52 · n 2746NCT01986881
43 other results
  • -2.3 vs -0.4 15 mg · wk 18 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.2 vs -0.7 15 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.4 vs -1.0 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • -3.8 vs -1.3 15 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.5 vs -0.4 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.4 5 mg · wk 18 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.7 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.0 vs -1.0 5 mg · wk 156 · n 1595 · Phase 3 · secondary NCT01986881
  • -3.4 vs -1.3 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.4 vs 0.1 15 mg · wk 52 · n 178 · Phase 3 · secondary NCT02033889
  • -3.6 vs -1.4 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -2.9 vs -1.3 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -3.2 vs -1.2 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -2.1 vs -0.3 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -4.6 vs -1.2 15 mg · wk 260 · n 530 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.9 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -3.2 vs 0.1 5 mg · wk 52 · n 181 · Phase 3 · secondary NCT02033889
  • -1.9 vs -0.3 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -3.7 vs -1.2 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -3.0 vs -1.3 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -1.4 vs 0.5 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -3.0 vs -1.2 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.2 vs -0.7 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.4 vs -0.5 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -3.6 vs -0.2 15 mg · wk 104 · n 145 · Phase 3 · secondary NCT02033889
  • -3.5 vs -0.9 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -3.2 vs -1.4 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • -3.0 vs -1.3 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -3.4 vs -1.3 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -1.3 vs 0.5 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -1.8 vs -0.7 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.5 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -3.8 vs -0.2 5 mg · wk 104 · n 148 · Phase 3 · secondary NCT02033889
  • -3.0 vs -0.9 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • -2.9 vs -0.9 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • -7.4 vs -1.0 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -4.2 vs -1.0 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -3.4 vs 0.9 15 mg · wk 52 · n 440 · Phase 3 · secondary NCT01999218
  • -3.7 vs -0.7 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -3.0 vs 0.9 5 mg · wk 52 · n 448 · Phase 3 · secondary NCT01999218
  • -2.7 vs -0.7 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -2.9 vs -0.7 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.5 vs -0.7 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110

HbA1c below 7%

Dapagliflozin
50.8% vs 31.6%+19.2 vs placebo10 mg AM · wk 24 · n 65NCT00528372
17 other results
  • 51.6% vs 31.6% 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • 31.8% vs 11.1% 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • 44.2% vs 31.6% 5 mg AM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • 44% vs 31.6% 5 mg PM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • 41.3% vs 31.6% 2.5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • 51.4% vs 31.6% 2.5 mg PM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • 40.6% vs 25.9% 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • 31.7% vs 13% 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • 38.8% vs 22.4% 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 37.5% vs 25.9% 5 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • 30.3% vs 13% 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • 32.5% vs 22.4% 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 33% vs 25.9% 2.5 mg · wk 24 · n 135 · Phase 3 · secondary NCT00528879
  • 26.8% vs 13% 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • 26.6% vs 10% wk 26 · n 64 · Phase 3 · secondary NCT03199053
  • 22.5% vs 34.6% 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT00643851
  • 52.4% vs 34.6% wk 24 · n 185 · Phase 3 · secondary NCT00643851
Ertugliflozin
28.2% vs 15.5%+12.7 vs placebo15 mg · wk 18 · n 2520NCT01986881
43 other results
  • 29% vs 17.4% 15 mg · wk 52 · n 2347 · Phase 3 · secondary NCT01986881
  • 23.8% vs 16.6% 15 mg · wk 104 · n 1541 · Phase 3 · secondary NCT01986881
  • 22.7% vs 16.9% 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • 22.7% vs 18.2% 15 mg · wk 208 · n 860 · Phase 3 · secondary NCT01986881
  • 28.4% vs 15.5% 5 mg · wk 18 · n 2544 · Phase 3 · secondary NCT01986881
  • 28.3% vs 17.4% 5 mg · wk 52 · n 2363 · Phase 3 · secondary NCT01986881
  • 23.9% vs 16.6% 5 mg · wk 104 · n 1570 · Phase 3 · secondary NCT01986881
  • 23.1% vs 16.9% 5 mg · wk 156 · n 1592 · Phase 3 · secondary NCT01986881
  • 35.8% vs 13.1% 15 mg · wk 26 · n 151 · Phase 3 · secondary NCT01958671
  • 40% vs 15.8% 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • 40.8% vs 16.2% 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • 21.1% vs 10.7% 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • 33.7% vs 19.1% 15 mg · wk 104 · n 205 · Phase 3 · secondary NCT02033889
  • 20% vs 16.5% 15 mg · wk 260 · n 529 · Phase 3 · secondary NCT01986881
  • 20.7% vs 10.7% 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • 24.9% vs 18.2% 5 mg · wk 208 · n 876 · Phase 3 · secondary NCT01986881
  • 39.9% vs 17% 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • 11.3% vs 12.1% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • 36.6% vs 30.6% 15 mg · wk 52 · n 205 · Phase 3 · secondary NCT02033889
  • 35.3% vs 15.8% 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • 34.8% vs 30.6% 5 mg · wk 52 · n 207 · Phase 3 · secondary NCT02033889
  • 24.6% vs 19.1% 5 mg · wk 104 · n 207 · Phase 3 · secondary NCT02033889
  • 18.6% vs 16.5% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • 27.8% vs 25% 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • 32.7% vs 12.8% 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • 32.7% vs 13.7% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • 28.2% vs 13.1% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • 32.1% vs 17% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • 16.2% vs 12.1% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • 38.2% vs 16.2% 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • 32.7% vs 25% 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • 37% vs 12.8% 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • 33.3% vs 13.7% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • 31.3% vs 8.3% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • 35.7% vs 8.3% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • 31.9% vs 32.8% 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • 26.4% vs 32.8% 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • 49.2% vs 32.8% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • 52.3% vs 32.8% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • 42.9% vs 15.6% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT01059825
  • 36.2% vs 15.6% 25 mg · wk 12 · n 47 · Phase 2 · secondary NCT01059825
  • 38.6% vs 15.6% 10 mg · wk 12 · n 44 · Phase 2 · secondary NCT01059825
  • 44% vs 15.6% 1 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825

Fasting plasma glucose, change

Dapagliflozin
-1.3 vs 0.2−1.5 vs placebowk 24 · n 222NCT00984867
34 other results
  • -1.6 vs -0.2 10 mg AM · wk 24 · n 70 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.2 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • -1.9 vs -0.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.2 vs 0.2 10mg · wk 24 · n 183 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.2 5mg · wk 24 · n 204 · Phase 3 · secondary NCT00673231
  • 0.1 vs 1.0 10 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -0.9 vs -0.1 10 mg AM · wk 1 · n 65 · Phase 3 · secondary NCT00528372
  • -0.7 vs 0.2 2.5mg · wk 24 · n 190 · Phase 3 · secondary NCT00673231
  • -1.1 vs -0.1 10 mg PM · wk 1 · n 60 · Phase 3 · secondary NCT00528372
  • -0.5 vs 1.0 20 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -1.3 vs -0.2 5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • -1.5 vs -0.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -0.9 vs -0.1 5 mg AM · wk 1 · n 56 · Phase 3 · secondary NCT00528372
  • -1.0 vs -0.1 5 mg PM · wk 1 · n 54 · Phase 3 · secondary NCT00528372
  • -0.8 vs -0.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -1.4 vs -0.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -0.2 vs -0.1 2.5 mg AM · wk 1 · n 57 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.1 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • -0.8 vs -0.1 2.5 mg PM · wk 1 · n 48 · Phase 3 · secondary NCT00528372
  • -1.3 vs -0.3 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.3 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.9 vs 0.1 10 mg · wk 1 · n 115 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.3 5 mg · wk 24 · n 136 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.1 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.4 vs -0.3 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.7 vs 0.1 5 mg · wk 1 · n 121 · Phase 3 · secondary NCT00528879
  • -1.0 vs -0.3 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -0.9 vs -0.1 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -0.3 vs 0.1 2.5 mg · wk 1 · n 120 · Phase 3 · secondary NCT00528879
  • -0.6 vs 0.5 wk 26 · n 75 · Phase 3 · secondary NCT03199053
  • -2.3 vs -1.9 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.6 vs -1.9 wk 24 · n 216 · Phase 3 · secondary NCT00859898
Ertugliflozin
-1.9 vs -0.9−1 vs placebo15 mg · wk 18 · n 2747NCT01986881
63 other results
  • -1.6 vs -0.5 15 mg · wk 52 · n 2328 · Phase 3 · secondary NCT01986881
  • -1.4 vs -0.2 15 mg · wk 104 · n 1536 · Phase 3 · secondary NCT01986881
  • -1.3 vs -0.2 15 mg · wk 156 · n 1567 · Phase 3 · secondary NCT01986881
  • -1.8 vs -0.9 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -0.9 vs 0.2 15 mg · wk 208 · n 861 · Phase 3 · secondary NCT01986881
  • -1.6 vs -0.5 5 mg · wk 52 · n 2352 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.2 5 mg · wk 104 · n 1562 · Phase 3 · secondary NCT01986881
  • -1.1 vs -0.2 5 mg · wk 156 · n 1579 · Phase 3 · secondary NCT01986881
  • -2.2 vs -0.1 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -1.8 vs -0.4 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -0.6 vs -0.3 15 mg · wk 260 · n 524 · Phase 3 · secondary NCT01986881
  • -1.8 vs -0.1 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -1.9 vs -0.7 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.6 vs -0.6 15 mg · wk 104 · n 144 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.1 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.4 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -0.8 vs 0.2 5 mg · wk 208 · n 868 · Phase 3 · secondary NCT01986881
  • -0.8 vs -0.3 5 mg · wk 260 · n 520 · Phase 3 · secondary NCT01986881
  • -2.4 vs 0.0 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -1.1 vs -0.3 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -1.9 vs -0.4 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -1.5 vs -0.8 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -1.5 vs 0.2 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -1.9 vs 0.0 5 mg · wk 26 · n 155 · Phase 3 · secondary NCT01958671
  • -1.5 vs -0.1 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -0.7 vs -0.3 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -2.1 vs -0.4 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.6 vs -0.8 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.7 5 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.4 vs 0.2 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -1.0 vs -0.6 5 mg · wk 104 · n 143 · Phase 3 · secondary NCT02033889
  • -1.1 vs 0.5 wk 24 · n 111 · Phase 3 · secondary NCT04029480
  • -0.7 vs 1.2 wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -4.7 vs 0.8 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.1 vs 0.8 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -2.0 vs -1.4 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -2.0 vs -1.4 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -2.7 vs -1.4 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.4 vs -1.4 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • -1.3 vs 0.1 5 mg · wk 12 · n 53 · Phase 2 · secondary NCT01059825
  • -1.4 vs 0.2 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 5 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.3 vs 0.3 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -1.3 vs -0.3 5 mg · wk 2 · n 34 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.1 25 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.5 vs 0.3 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -1.8 vs -0.3 25 mg · wk 2 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.1 10 mg · wk 12 · n 51 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.2 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.3 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -1.5 vs 0.3 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.1 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.2 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.8 vs 0.2 1 mg · wk 4 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.6 vs -0.3 1 mg · wk 2 · n 35 · Phase 2 · secondary NCT01096667
  • -0.8 vs 0.3 1 mg · wk 2 · n 51 · Phase 2 · secondary NCT01059825

3-point MACE (% with event)

Dapagliflozin
—Not posted · NCT04170998
Ertugliflozin
—Not posted · NCT03717194
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. Dapagliflozin: 8 of 8 rows · Ertugliflozin: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDapagliflozin
Rows use multiple source trials
Ertugliflozin
Rows use multiple source trials
DBP
absolute change · mmHg
-0.25 vs 2.36 Glimepiride mmHg @ 52wka,b,c,d
NCT02564926 · Phase 4 · registry result, not featured evidence
-0.97 vs 1.21 placebo mmHg @ 26wk15 mg + 100 mge,a,b,c,d
NCT02226003 · Phase 3 · combination
show 1 more dose
-0.44 vs 1.21 placebo mmHg @ 26wk5 mg + 100 mg
NCT02226003 · Phase 3 · combination
LVGLS
absolute change · percentage points
0.30769% (n=24) vs -0.00352% (n=24) placebo @ 6wk10 mga,f,c,g
NCT03387683 · Phase 4 · registry result, not featured evidence
16.6% (n=51) vs 16.4% (n=51) placebo @ 24wka,f,c,g
NCT03717194 · Phase 3 · registry result, not featured evidence
SBP
absolute change · mmHg
-2.18 vs 4.63 Glimepiride mmHg @ 52wka,b,c,d
NCT02564926 · Phase 4 · registry result, not featured evidence
-3.98 vs 2.41 placebo mmHg @ 26wk15 mg + 100 mge,a,b,c,d
NCT02226003 · Phase 3 · combination
show 1 more dose
-2.04 vs 2.41 placebo mmHg @ 26wk5 mg + 100 mg
NCT02226003 · Phase 3 · combination
Seated SBP
absolute change · mmHg
-4.04 vs -0.27 placebo mmHg @ 8wk10 mgb,h
NCT01392677 · Phase 3 · combination
1 other source trial
-5.98 vs -5.12 placebo mmHg @ 8wk
NCT00984867 · Phase 3
-3.46 vs 2.72 placebo mmHg @ 312wk15 mge,b,h
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more dose
1.28 vs 2.72 placebo mmHg @ 312wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Dropout rate
18.6%10 mg AMi
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
14.5%10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.8%10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
18.8%5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
16.2%5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.6%5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.7%2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
13.4%2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
0%20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
14.2%Dapagliflozin
NCT00859898 · Phase 3
13.3%Dapagliflozin + Metformin XR
NCT00859898 · Phase 3 · combination
16.3%5 mg
NCT00643851 · Phase 3
8.8%Dapagliflozin 5 mg + Metformin XR
NCT00643851 · Phase 3 · combination
11.9%10 mg
NCT00528879 · Phase 3 · combination
10.9%5 mg
NCT00528879 · Phase 3 · combination
—5.0 mg
NCT00528879 · Phase 3 · combination
12.4%2.5 mg
NCT00528879 · Phase 3 · combination
20.7%
NCT00660907 · Phase 3 · combination
6.6%10 mg
NCT00680745 · Phase 3 · combination
9%5 mg
NCT00680745 · Phase 3 · combination
9.1%2.5 mg
NCT00680745 · Phase 3 · combination
7.3%10 mg
NCT01392677 · Phase 3 · combination
10%10MG
NCT00683878 · Phase 3 · combination
11.3%5MG
NCT00683878 · Phase 3 · combination
7.6%
NCT00984867 · Phase 3
9.2%10mg
NCT00673231 · Phase 3
12.3%5mg
NCT00673231 · Phase 3
10.9%2.5mg
NCT00673231 · Phase 3
2.5%10mg QD
NCT02413398 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3 · combination
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
6.2%Dapagliflozin
NCT03199053 · Phase 3 · background therapy
1.3%10 mg
NCT01730534 · Phase 3
16.7%Dapagliflozin/Hyperfiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
16.7%Dapagliflozin/Normofiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
0%Normal Glucose Tolerance (NGT) on
NCT02981966 · Phase 4 · registry result, not featured evidence
0%T2DM Individuals on Dapagliflozin
NCT02981966 · Phase 4 · registry result, not featured evidence
0%Byetta / Bydureon
NCT02981069 · Phase 4 · registry result, not featured evidence
0%Byetta/Bydureon Plus Dapagliflozin
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
12.9%
NCT03782259 · Phase 4 · registry result, not featured evidence
16%
NCT02235298 · Phase 4 · registry result, not featured evidence
—
NCT02796170 · Phase 4 · registry result, not featured evidence
—10mg
NCT03338855 · Phase 4 · registry result, not featured evidence
—
NCT02973477 · Phase 4 · registry result, not featured evidence
7.4%10 mg
NCT03387683 · Phase 4 · registry result, not featured evidence
7.7%
NCT02433678 · Phase 4 · registry result, not featured evidence
0%10mg Once Daily
NCT02682563 · Phase 4 · registry result, not featured evidence
8.3%
NCT03074630 · Phase 4 · registry result, not featured evidence
13.3%
NCT02564926 · Phase 4 · registry result, not featured evidence
—15 mgi
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
—15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.6%15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—15 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
12%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.8%15 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.2%5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.2%15 mg
NCT02033889 · Phase 3
9.7%5 mg
NCT02033889 · Phase 3
22.9%15 mg
NCT01999218 · Phase 3
24.3%5 mg
NCT01999218 · Phase 3
12.5%15 mg
NCT02099110 · Phase 3
9.6%5 mg
NCT02099110 · Phase 3
11%15 mg + 100 mg
NCT02099110 · Phase 3 · combination
9.1%5 mg + 100 mg
NCT02099110 · Phase 3 · combination
7.7%15 mg
NCT02036515 · Phase 3
—15 mg
NCT02036515 · Phase 3 · combination
3.2%5 mg
NCT02036515 · Phase 3
—5 mg
NCT02036515 · Phase 3 · combination
1%15 mg + 100 mg
NCT02226003 · Phase 3 · combination
2%5 mg + 100 mg
NCT02226003 · Phase 3 · combination
9%15 mg
NCT01986855 · Phase 3
8.2%5 mg
NCT01986855 · Phase 3
—15 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
5.3%15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
4.1%5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
0%
NCT03416270 · Phase 2 · registry result, not featured evidence
5.3%5 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
7.7%25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
5.1%1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
39.3%
NCT04167761 · Phase 1 · registry result, not featured evidence
—15 mg Oral + 100 ug Oral
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
—15 mg Oral + 100 ug IV
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—4 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—1 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
8.6%10 mg AMi
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
3.9%10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.1%5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
4.4%5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.1%2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
—20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
4.1%Dapagliflozin
NCT00859898 · Phase 3
1.9%Dapagliflozin + Metformin XR
NCT00859898 · Phase 3 · combination
3%5 mg
NCT00643851 · Phase 3
1%Dapagliflozin 5 mg + Metformin XR
NCT00643851 · Phase 3 · combination
3%10 mg
NCT00528879 · Phase 3 · combination
1.5%5 mg
NCT00528879 · Phase 3 · combination
—5.0 mg
NCT00528879 · Phase 3 · combination
2.9%2.5 mg
NCT00528879 · Phase 3 · combination
8.1%
NCT00660907 · Phase 3 · combination
2%10 mg
NCT00680745 · Phase 3 · combination
2.1%5 mg
NCT00680745 · Phase 3 · combination
3.2%2.5 mg
NCT00680745 · Phase 3 · combination
0.9%10 mg
NCT01392677 · Phase 3 · combination
2.1%10MG
NCT00683878 · Phase 3 · combination
2.1%5MG
NCT00683878 · Phase 3 · combination
3.1%
NCT00984867 · Phase 3
3.1%10mg
NCT00673231 · Phase 3
4.2%5mg
NCT00673231 · Phase 3
2.5%2.5mg
NCT00673231 · Phase 3
—10mg QD
NCT02413398 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3 · combination
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
—Dapagliflozin
NCT03199053 · Phase 3 · background therapy
—10 mg
NCT01730534 · Phase 3
—Dapagliflozin/Hyperfiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
—Dapagliflozin/Normofiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
—Normal Glucose Tolerance (NGT) on
NCT02981966 · Phase 4 · registry result, not featured evidence
—T2DM Individuals on Dapagliflozin
NCT02981966 · Phase 4 · registry result, not featured evidence
—Byetta / Bydureon
NCT02981069 · Phase 4 · registry result, not featured evidence
—Byetta/Bydureon Plus Dapagliflozin
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
—
NCT03782259 · Phase 4 · registry result, not featured evidence
4%
NCT02235298 · Phase 4 · registry result, not featured evidence
—
NCT02796170 · Phase 4 · registry result, not featured evidence
—10mg
NCT03338855 · Phase 4 · registry result, not featured evidence
—
NCT02973477 · Phase 4 · registry result, not featured evidence
—10 mg
NCT03387683 · Phase 4 · registry result, not featured evidence
—
NCT02433678 · Phase 4 · registry result, not featured evidence
—10mg Once Daily
NCT02682563 · Phase 4 · registry result, not featured evidence
—
NCT03074630 · Phase 4 · registry result, not featured evidence
—
NCT02564926 · Phase 4 · registry result, not featured evidence
—15 mgi
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
—15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—15 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.7%15 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.6%5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.5%15 mg
NCT02033889 · Phase 3
0.5%5 mg
NCT02033889 · Phase 3
1.6%15 mg
NCT01999218 · Phase 3
2%5 mg
NCT01999218 · Phase 3
2%15 mg
NCT02099110 · Phase 3
1.2%5 mg
NCT02099110 · Phase 3
0.8%15 mg + 100 mg
NCT02099110 · Phase 3 · combination
1.2%5 mg + 100 mg
NCT02099110 · Phase 3 · combination
0.6%15 mg
NCT02036515 · Phase 3
—15 mg
NCT02036515 · Phase 3 · combination
0.6%5 mg
NCT02036515 · Phase 3
—5 mg
NCT02036515 · Phase 3 · combination
—15 mg + 100 mg
NCT02226003 · Phase 3 · combination
—5 mg + 100 mg
NCT02226003 · Phase 3 · combination
0%15 mg
NCT01986855 · Phase 3
0.6%5 mg
NCT01986855 · Phase 3
—15 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
0.6%15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
1.2%5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
—
NCT03416270 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—
NCT04167761 · Phase 1 · registry result, not featured evidence
—15 mg Oral + 100 ug Oral
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
—15 mg Oral + 100 ug IV
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
—15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
—15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—4 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—1 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
Serious AEs
1.4%10 mg AMi
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
3.9%10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.3%5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
7.4%5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.2%2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.4%2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
4.2%20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
2.3%Dapagliflozin
NCT00859898 · Phase 3
1.4%Dapagliflozin + Metformin XR
NCT00859898 · Phase 3 · combination
4.4%5 mg
NCT00643851 · Phase 3
3.1%Dapagliflozin 5 mg + Metformin XR
NCT00643851 · Phase 3 · combination
10.4%10 mg
NCT00528879 · Phase 3 · combination
—5 mg
NCT00528879 · Phase 3 · combination
6.6%5.0 mg
NCT00528879 · Phase 3 · combination
10.9%2.5 mg
NCT00528879 · Phase 3 · combination
8.6%
NCT00660907 · Phase 3 · combination
6%10 mg
NCT00680745 · Phase 3 · combination
6.9%5 mg
NCT00680745 · Phase 3 · combination
7.1%2.5 mg
NCT00680745 · Phase 3 · combination
0.9%10 mg
NCT01392677 · Phase 3 · combination
1.4%10MG
NCT00683878 · Phase 3 · combination
2.8%5MG
NCT00683878 · Phase 3 · combination
4.4%
NCT00984867 · Phase 3
7.1%10mg
NCT00673231 · Phase 3
4.7%5mg
NCT00673231 · Phase 3
7.4%2.5mg
NCT00673231 · Phase 3
5.6%10mg QD
NCT02413398 · Phase 3
0%10 mg
NCT03199053 · Phase 3
4.8%10 mg
NCT03199053 · Phase 3
0%10 mg
NCT03199053 · Phase 3 · combination
1.2%5 mg
NCT03199053 · Phase 3
0%5 mg
NCT03199053 · Phase 3
9.1%5 mg
NCT03199053 · Phase 3
—Dapagliflozin
NCT03199053 · Phase 3 · background therapy
37.4%10 mg
NCT01730534 · Phase 3
0%Dapagliflozin/Hyperfiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
0%Dapagliflozin/Normofiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
0%Normal Glucose Tolerance (NGT) on
NCT02981966 · Phase 4 · registry result, not featured evidence
0%T2DM Individuals on Dapagliflozin
NCT02981966 · Phase 4 · registry result, not featured evidence
0%Byetta / Bydureon
NCT02981069 · Phase 4 · registry result, not featured evidence
0%Byetta/Bydureon Plus Dapagliflozin
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
—
NCT03782259 · Phase 4 · registry result, not featured evidence
0%
NCT02235298 · Phase 4 · registry result, not featured evidence
0%
NCT02796170 · Phase 4 · registry result, not featured evidence
0%10mg
NCT03338855 · Phase 4 · registry result, not featured evidence
2.3%
NCT02973477 · Phase 4 · registry result, not featured evidence
0%10 mg
NCT03387683 · Phase 4 · registry result, not featured evidence
0%
NCT02433678 · Phase 4 · registry result, not featured evidence
0%10mg Once Daily
NCT02682563 · Phase 4 · registry result, not featured evidence
—
NCT03074630 · Phase 4 · registry result, not featured evidence
10%
NCT02564926 · Phase 4 · registry result, not featured evidence
7.3%15 mgi
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
7.1%15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
34.1%15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.9%15 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9.5%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
7%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
34.9%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.3%5 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
3.9%15 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.1%5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.8%15 mg
NCT02033889 · Phase 3
9.7%5 mg
NCT02033889 · Phase 3
7.4%15 mg
NCT01999218 · Phase 3
9.2%5 mg
NCT01999218 · Phase 3
2%15 mg
NCT02099110 · Phase 3
4.8%5 mg
NCT02099110 · Phase 3
4.9%15 mg + 100 mg
NCT02099110 · Phase 3 · combination
3.7%5 mg + 100 mg
NCT02099110 · Phase 3 · combination
—15 mg
NCT02036515 · Phase 3
2%15 mg
NCT02036515 · Phase 3 · combination
—5 mg
NCT02036515 · Phase 3
8.3%5 mg
NCT02036515 · Phase 3 · combination
3.1%15 mg + 100 mg
NCT02226003 · Phase 3 · combination
2%5 mg + 100 mg
NCT02226003 · Phase 3 · combination
19.4%15 mg
NCT01986855 · Phase 3
16.5%5 mg
NCT01986855 · Phase 3
3.8%15 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
3.2%5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
4.5%5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
5.9%15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
5.3%5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
17.6%
NCT03416270 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
3.6%5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
1.8%25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
0%
NCT04167761 · Phase 1 · registry result, not featured evidence
0%15 mg Oral + 100 ug Oral
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
0%15 mg Oral + 100 ug IV
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%4 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
0%2 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
0%2 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
0%1 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
10 mg AMi
nasopharyngitis 14.3% (placebo 9.3%)
arthralgia 8.6% (placebo 4%)
headache 8.6% (placebo 12%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 42 more results
10 mg PM
headache 13.2% (placebo 12%)
upper respiratory tract infection 11.8% (placebo 5.3%)
back pain 9.2% (placebo 6.7%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg AM
pharyngitis 9.4% (placebo 8%)
arthralgia 7.8% (placebo 4%)
headache 7.8% (placebo 12%)
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
5 mg PM
headache 16.2% (placebo 12%)
nasopharyngitis 13.2% (placebo 9.3%)
arthralgia 11.8% (placebo 4%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg AM
nasopharyngitis 16.9% (placebo 9.3%)
influenza 10.8% (placebo 4%)
arthralgia 9.2% (placebo 4%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg PM
nasopharyngitis 16.4% (placebo 9.3%)
abdominal pain 9% (placebo 2.7%)
dizziness 9% (placebo 2.7%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
10 mg
back pain 12.5% (placebo 8.7%)
headache 12.5% (placebo 8.7%)
fatigue 8.3% (placebo 0%)
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
20 mg
nausea 12.5% (placebo 4.3%)
pollakiuria 12.5% (placebo 17.4%)
vomiting 12.5% (placebo 0%)
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
urinary tract infection 7.8%
vulvovaginal mycotic infection 5%
diarrhoea 2.7%
NCT00859898 · Phase 3
diarrhoea 7.1%
vulvovaginal mycotic infection 3.3%
urinary tract infection 2.8%
NCT00859898 · Phase 3 · combination
5 mg
dyslipidaemia 5.4%
upper respiratory tract infection 4.9%
urinary tract infection 4.4%
NCT00643851 · Phase 3
diarrhoea 7.7%
nausea 5.7%
upper respiratory tract infection 5.2%
NCT00643851 · Phase 3 · combination
10 mg
back pain 13.3% (placebo 8%)
influenza 12.6% (placebo 10.9%)
diarrhoea 11.9% (placebo 7.3%)
NCT00528879 · Phase 3 · combination
5.0 mg
influenza 14.6% (placebo 10.9%)
headache 9.5% (placebo 5.8%)
arthralgia 7.3% (placebo 5.1%)
NCT00528879 · Phase 3 · combination
2.5 mg
influenza 13.9% (placebo 10.9%)
nasopharyngitis 11.7% (placebo 8.8%)
back pain 8% (placebo 8%)
NCT00528879 · Phase 3 · combination
nasopharyngitis 10.6%
hypertension 7.4%
influenza 7.4%
NCT00660907 · Phase 3 · combination
10 mg
hypoglycemia 7.9% (placebo 4.8%)
nasopharyngitis 3.3% (placebo 2.7%)
hypertension 1.3% (placebo 4.1%)
NCT00680745 · Phase 3 · combination
5 mg
hypoglycemia 6.9% (placebo 4.8%)
nasopharyngitis 5.5% (placebo 2.7%)
hypertension 1.4% (placebo 4.1%)
NCT00680745 · Phase 3 · combination
2.5 mg
hypoglycemia 7.1% (placebo 4.8%)
hypertension 5.2% (placebo 4.1%)
nasopharyngitis 1.9% (placebo 2.7%)
NCT00680745 · Phase 3 · combination
10 mg
urinary tract infection 4.6% (placebo 6.4%)
NCT01392677 · Phase 3 · combination
10MG
dyslipidaemia 9.3% (placebo 4.3%)
nasopharyngitis 7.9% (placebo 3.6%)
diarrhoea 6.4% (placebo 4.3%)
NCT00683878 · Phase 3 · combination
5MG
upper respiratory tract infection 6.4% (placebo 5.8%)
dyslipidaemia 5.7% (placebo 4.3%)
nasopharyngitis 5% (placebo 3.6%)
NCT00683878 · Phase 3 · combination
nasopharyngitis 4% (placebo 6.2%)
NCT00984867 · Phase 3
10mg
hypoglycemia 44.9% (placebo 42.1%)
nasopharyngitis 8.7% (placebo 11.2%)
urinary tract infection 5.6% (placebo 3%)
NCT00673231 · Phase 3
5mg
hypoglycemia 47.6% (placebo 42.1%)
nasopharyngitis 13.7% (placebo 11.2%)
hypertension 6.1% (placebo 8.1%)
NCT00673231 · Phase 3
2.5mg
hypoglycemia 55% (placebo 42.1%)
nasopharyngitis 13.9% (placebo 11.2%)
hypertension 5.4% (placebo 8.1%)
NCT00673231 · Phase 3
10 mg
abdominal pain 4.8% (placebo 2.6%)
abdominal pain upper 4.8% (placebo 0%)
bronchitis 4.8% (placebo 0%)
NCT03199053 · Phase 3
10 mg
dysmenorrhoea 9.5% (placebo 2.6%)
headache 9.5% (placebo 1.3%)
conjunctivitis allergic 4.8% (placebo 0%)
NCT03199053 · Phase 3
10 mg
pharyngotonsillitis 14.3% (placebo 1.3%)
tonsillitis 14.3% (placebo 0%)
abdominal pain 0% (placebo 2.6%)
NCT03199053 · Phase 3 · combination
5 mg
headache 7.4% (placebo 1.3%)
hypertriglyceridaemia 4.9% (placebo 1.3%)
diarrhoea 3.7% (placebo 3.9%)
NCT03199053 · Phase 3
5 mg
headache 9.1% (placebo 1.3%)
nasopharyngitis 3.6% (placebo 2.6%)
anxiety 1.8% (placebo 0%)
NCT03199053 · Phase 3
5 mg
influenza 5.5% (placebo 2.6%)
abdominal pain upper 3.6% (placebo 0%)
headache 3.6% (placebo 1.3%)
NCT03199053 · Phase 3
10 mg
renal impairment 1.4% (placebo 1.7%)
acute kidney injury 1% (placebo 1.3%)
chronic kidney disease 0.9% (placebo 1.2%)
NCT01730534 · Phase 3
genital mycotic infection 13.3%
mild hypoglycemia 0%
NCT02911792 · Phase 4 · registry result, not featured evidence
genital mycotic infection 26.7%
mild hypoglycemia 0%
NCT02911792 · Phase 4 · registry result, not featured evidence
transcient syncope 12.5% (placebo 0%)
NCT02981966 · Phase 4 · registry result, not featured evidence
transcient syncope 0% (placebo 0%)
NCT02981966 · Phase 4 · registry result, not featured evidence
nausea and vomiting 24% (placebo 0%)
genital mycosis 0% (placebo 0%)
NCT02981069 · Phase 4 · registry result, not featured evidence
nausea and vomiting 20% (placebo 0%)
genital mycosis 8% (placebo 0%)
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
dysuria 12% (placebo 0%)
frequency of urination 12% (placebo 0%)
balanitis 2% (placebo 0%)
NCT02235298 · Phase 4 · registry result, not featured evidence
cold like symptoms 4.5%
genital yeast infection 4.5%
abrasion of left cornea 2.3%
NCT02973477 · Phase 4 · registry result, not featured evidence
10mg Once Daily
genital fungal infections 20.8%
NCT02682563 · Phase 4 · registry result, not featured evidence
nasopharyngitis 6.7%
toothache 6.7%
hypoglycaemia 5%
NCT02564926 · Phase 4 · registry result, not featured evidence
15 mgi
hypoglycaemia 30.3% (placebo 31.4%)
nasopharyngitis 3.5% (placebo 3.2%)
upper respiratory tract infection 2.7% (placebo 2.6%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 44 more results
15 mg
hypoglycaemia 16.8% (placebo 31.4%)
nasopharyngitis 4.4% (placebo 3.2%)
dizziness 3.5% (placebo 1.2%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
15 mg
hypoglycaemia 31.1% (placebo 31.4%)
urinary tract infection 9.5% (placebo 2%)
nasopharyngitis 7.4% (placebo 3.2%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
15 mg
hypoglycaemia 5.6% (placebo 31.4%)
urinary tract infection 1.9% (placebo 2%)
back pain 0% (placebo 0.6%)
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 29% (placebo 31.4%)
dizziness 2.3% (placebo 1.2%)
upper respiratory tract infection 2.3% (placebo 2.6%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 13% (placebo 31.4%)
hypertension 4% (placebo 0.6%)
hyperglycaemia 3% (placebo 1.7%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 32.2% (placebo 31.4%)
urinary tract infection 9.3% (placebo 2%)
upper respiratory tract infection 7.2% (placebo 2.6%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 5.5% (placebo 31.4%)
back pain 3.6% (placebo 0.6%)
hypertension 3.6% (placebo 0.6%)
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15 mg
nasopharyngitis 7.2% (placebo 3.9%)
upper respiratory tract infection 6.6% (placebo 5.9%)
urinary tract infection 6.6% (placebo 12.4%)
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
urinary tract infection 8.3% (placebo 12.4%)
vulvovaginal mycotic infection 7.7% (placebo 1.3%)
constipation 7.1% (placebo 2.6%)
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
15 mg
upper respiratory tract infection 10.2% (placebo 15.8%)
back pain 9.8% (placebo 4.8%)
hypoglycaemia 8.8% (placebo 20.6%)
NCT02033889 · Phase 3
5 mg
upper respiratory tract infection 11.1% (placebo 15.8%)
headache 6.8% (placebo 4.8%)
hypoglycaemia 6.8% (placebo 20.6%)
NCT02033889 · Phase 3
15 mg
urinary tract infection 6.4%
hypoglycaemia 5.7%
headache 4.4%
NCT01999218 · Phase 3
5 mg
upper respiratory tract infection 6.1%
urinary tract infection 6.1%
headache 5.6%
NCT01999218 · Phase 3
15 mg
urinary tract infection 7.7%
hypoglycaemia 5.2%
nasopharyngitis 5.2%
NCT02099110 · Phase 3
5 mg
urinary tract infection 8%
hypoglycaemia 4.8%
nasopharyngitis 2.4%
NCT02099110 · Phase 3
15 mg + 100 mg
hypoglycaemia 8.2%
nasopharyngitis 4.9%
urinary tract infection 3.3%
NCT02099110 · Phase 3 · combination
5 mg + 100 mg
urinary tract infection 5.8%
nasopharyngitis 4.9%
hypoglycaemia 3.7%
NCT02099110 · Phase 3 · combination
15 mg
nasopharyngitis 3.9% (placebo 3.3%)
hypoglycaemia 3.3% (placebo 7.2%)
urinary tract infection 3.3% (placebo 5.2%)
NCT02036515 · Phase 3 · combination
5 mg
back pain 5.1% (placebo 3.9%)
nasopharyngitis 5.1% (placebo 3.3%)
hypoglycaemia 4.5% (placebo 7.2%)
NCT02036515 · Phase 3 · combination
15 mg + 100 mg
urinary tract infection 2.1% (placebo 1%)
hyperglycaemia 1% (placebo 6.2%)
blood glucose increased 0% (placebo 7.2%)
NCT02226003 · Phase 3 · combination
5 mg + 100 mg
urinary tract infection 5.1% (placebo 1%)
blood glucose increased 3.1% (placebo 7.2%)
hyperglycaemia 0% (placebo 6.2%)
NCT02226003 · Phase 3 · combination
15 mg
hypoglycaemia 20.6% (placebo 29.2%)
urinary tract infection 7.7% (placebo 9.7%)
upper respiratory tract infection 7.1% (placebo 4.5%)
NCT01986855 · Phase 3
5 mg
hypoglycaemia 31% (placebo 29.2%)
diarrhoea 6.3% (placebo 5.8%)
cough 5.7% (placebo 1.3%)
NCT01986855 · Phase 3
15 mg
hypoglycaemia 19.2% (placebo 12.7%)
nausea 15.4% (placebo 7.3%)
vomiting 15.4% (placebo 5.5%)
NCT04029480 · Phase 3 · registry result, not featured evidence
5 mg
upper respiratory tract infection 14.3% (placebo 10.9%)
hypoglycaemia 11.1% (placebo 12.7%)
covid-19 7.9% (placebo 7.3%)
NCT04029480 · Phase 3 · registry result, not featured evidence
5 mg
hypoglycaemia 11.5% (placebo 12.7%)
nausea 7.7% (placebo 7.3%)
vomiting 7.7% (placebo 5.5%)
NCT04029480 · Phase 3 · registry result, not featured evidence
5 mg
nausea 13.6% (placebo 7.3%)
abdominal pain 9.1% (placebo 5.5%)
diarrhoea 9.1% (placebo 7.3%)
NCT04029480 · Phase 3 · registry result, not featured evidence
15 mg
hyperuricaemia 5.3% (placebo 12%)
hypoglycaemia 5.3% (placebo 1.2%)
nasopharyngitis 5.3% (placebo 6.6%)
NCT02630706 · Phase 3 · registry result, not featured evidence
5 mg
nasopharyngitis 5.3% (placebo 6.6%)
hypoglycaemia 3.5% (placebo 1.2%)
hyperuricaemia 2.9% (placebo 12%)
NCT02630706 · Phase 3 · registry result, not featured evidence
5 mg
genital infection fungal 7.9% (placebo 0%)
athralgia 5.3% (placebo 0%)
nasopharyngitis 5.3% (placebo 0%)
NCT01096667 · Phase 2 · registry result, not featured evidence
25 mg
fatigue 5.1% (placebo 0%)
polyuria 5.1% (placebo 0%)
dizziness 2.6% (placebo 5.3%)
NCT01096667 · Phase 2 · registry result, not featured evidence
1 mg
musculoskeletal pain 5.1% (placebo 0%)
upper respiratory tract infection 2.6% (placebo 5.3%)
urinary tract infection 2.6% (placebo 2.6%)
NCT01096667 · Phase 2 · registry result, not featured evidence
5 mg
arthralgia 10.9% (placebo 1.9%)
headache 7.3% (placebo 3.7%)
hypoglycaemia 5.5% (placebo 0%)
NCT01059825 · Phase 2 · registry result, not featured evidence
25 mg
genital infection fungal 7.3% (placebo 1.9%)
diarrhoea 5.5% (placebo 1.9%)
upper respiratory tract infection 5.5% (placebo 3.7%)
NCT01059825 · Phase 2 · registry result, not featured evidence
10 mg
urinary tract infection 9.1% (placebo 7.4%)
genital infection fungal 5.5% (placebo 1.9%)
upper respiratory tract infection 5.5% (placebo 3.7%)
NCT01059825 · Phase 2 · registry result, not featured evidence
1 mg
arthralgia 3.7% (placebo 1.9%)
diarrhoea 3.7% (placebo 1.9%)
upper respiratory tract infection 3.7% (placebo 3.7%)
NCT01059825 · Phase 2 · registry result, not featured evidence
15 mg Oral + 100 ug Oral
nasal congestion 12.5%
back pain 0%
headache 0%
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
15 mg Oral + 100 ug IV
headache 25%
back pain 12.5%
nasal congestion 0%
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
15 mg
decreased appetite 12.5%
headache 12.5%
tachycardia 12.5%
NCT02115347 · Phase 1 · registry result, not featured evidence
15 mg
arthralgia 12.5%
back pain 12.5%
dizziness 12.5%
NCT02115347 · Phase 1 · registry result, not featured evidence
4 mg Once Daily
diarrhoea 11.5%
headache 7.7%
abdominal pain 3.8%
NCT01054300 · Phase 1 · registry result, not featured evidence
2 mg Once Daily
headache 11.5%
constipation 3.8%
dizziness 3.8%
NCT01054300 · Phase 1 · registry result, not featured evidence
2 mg Twice Daily
abdominal pain 3.8%
diarrhoea 3.8%
dry mouth 3.8%
NCT01054300 · Phase 1 · registry result, not featured evidence
1 mg Twice Daily
headache 12%
back pain 4%
dyspepsia 4%
NCT01054300 · Phase 1 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 52 weeks versus 26 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation context differs: registered conditions differ.
  7. gAssessment timepoints differ: 6 weeks versus 24 weeks.
  8. hAssessment timepoints differ: 8 weeks versus 312 weeks.
  9. iPopulation comparability has not been reviewed for 44 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dapagliflozin

Fasting Plasma Glucose -4.68 mmol/L @ 24wk10 mg AM
absolute change · mmol/L
No placebo or comparator arm
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -84.3 mg/dL as posted
show 5 more results
-4.12 mmol/L @ 1wk*10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -74.3 mg/dL as posted
-1.62 mmol/L @ 26wk10 mg
NCT03199053 · Phase 3
-4.27 mmol/L @ 24wk*5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -77 mg/dL as posted
-3.01 mmol/L @ 1wk*5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -54.3 mg/dL as posted
-0.98 mmol/L @ 26wk5 mg
NCT03199053 · Phase 3
Weight -1.9 kg @ 24wk10 mg AM
absolute change · kg
No placebo or comparator arm
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
-2.06 kg @ 24wk5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than or Equal to 6.5 23.1% (n=14) vs 14.5% (n=11) placebo @ 24wk10 mg AM
responder rate · % of participants
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 8 more results
26% (n=73) vs 14.5% (n=11) placebo @ 24wk10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
26.6% (n=17) vs 14.5% (n=11) placebo @ 24wk5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
25.8% (n=63) vs 14.5% (n=11) placebo @ 24wk5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
27.2% (n=17) vs 14.5% (n=11) placebo @ 24wk2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
33.4% (n=62) vs 14.5% (n=11) placebo @ 24wk2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
25.2% (n=36) vs 13.8% (n=18) placebo @ 24wk10 mg
NCT00528879 · Phase 3 · combination
14.5% (n=18) vs 13.8% (n=18) placebo @ 24wk5 mg
NCT00528879 · Phase 3 · combination
20.7% (n=29) vs 13.8% (n=18) placebo @ 24wk2.5 mg
NCT00528879 · Phase 3 · combination
HbA1c -2.66% (n=32) @ 24wk10 mg AM
absolute change · percentage points
No placebo or comparator arm
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-0.74% (n=19) @ 26wk10 mg
NCT03199053 · Phase 3
-2.88% (n=25) @ 24wk5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.71% (n=21) @ 26wk5 mg
NCT03199053 · Phase 3
HbA1c 7.0 or Less 13% (n=23) vs 5.3% (n=19) placebo @ 12wk10 mg
event count · % of participants
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 3 Participants as posted
show 1 more result
4.3% (n=23) vs 5.3% (n=19) placebo @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 1 Participants as posted
HbA1c Less Than or Equal to 6.5 4.3% (n=23) vs 0% (n=19) placebo @ 12wk10 mg
event count · % of participants
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 1 Participants as posted
show 1 more result
0% (n=23) vs 0% (n=19) placebo @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 0 Participants as posted
HbA1C Decrease at Least 0.5 65.2% (n=23) vs 15.8% (n=19) placebo @ 12wk10 mg
event count · % of participants
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 15 Participants as posted
show 1 more result
65.2% (n=23) vs 15.8% (n=19) placebo @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 15 Participants as posted
TDDI Change Units Per -1.35 vs 1.69 placebo per day @ 12wk10 mg
absolute change · per day
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
show 4 more results
-1.16 vs 5.08 placebo per day @ 24wk10mg
NCT00673231 · Phase 3
-0.83 vs 1.69 placebo per day @ 12wk20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
-0.61 vs 5.08 placebo per day @ 24wk5mg
NCT00673231 · Phase 3
-1.8 vs 5.08 placebo per day @ 24wk2.5mg
NCT00673231 · Phase 3
HbA1c Less Than 7 46.6% (n=202) vs 35.5% (n=203) Metformin XR @ 24wk
absolute value · percentage points
NCT00859898 · Phase 3 · combination
show 1 more result
31.7% (n=216) vs 35.5% (n=203) Metformin XR @ 24wk
NCT00859898 · Phase 3
Weight Loss 5% 33.3% (n=400) vs 2.5% (n=401) Glipizide Plus Metformin @ 52wk
responder rate · % of participants
NCT00660907 · Phase 3 · combination
OGTT 2 h Change mg/dL -34.9 vs -6 placebo mg/dL @ 24wk10 mg
absolute change · mg/dL
NCT00680745 · Phase 3 · combination
show 2 more results
-32 vs -6 placebo mg/dL @ 24wk5 mg
NCT00680745 · Phase 3 · combination
-37.5 vs -6 placebo mg/dL @ 24wk2.5 mg
NCT00680745 · Phase 3 · combination
PPG 2h Change mg/dL -3.75 vs -0.78 placebo mmol/L @ 24wk10MG
absolute change · mmol/L
NCT00683878 · Phase 3 · combination · converted to mmol/L from -67.5 mg/dL as posted
show 2 more results
-3.61 vs -0.78 placebo mmol/L @ 24wk*5MG
NCT00683878 · Phase 3 · combination · converted to mmol/L from -65.1 mg/dL as posted
-1.2 vs -0.38 placebo mmol/L @ 24wk*
NCT00984867 · Phase 3 · converted to mmol/L from -21.65 mg/dL as posted

+ 33 further endpoints in the CSV export.

Ertugliflozin

MACE Plus 4.67 vs 4.92 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
4.42 vs 4.92 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Myocardial Infarction 2 vs 1.7 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
1.55 vs 1.7 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Total MACE 4.91 vs 4.59 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
4.35 vs 4.59 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
CV Death or HF Hospitalization Total 2.71 vs 3.42 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
2.92 vs 3.42 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than 6 5 8.8% (n=2520) vs 4.7% (n=2727) placebo @ 18wk15 mg
responder rate · % of participants
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 23 more results
10.9% (n=2347) vs 6.1% (n=2311) placebo @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.6% (n=1541) vs 5.8% (n=1496) placebo @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
8% (n=1578) vs 5.8% (n=1507) placebo @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.1% (n=860) vs 7.5% (n=786) placebo @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.5% (n=529) vs 6.5% (n=478) placebo @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.2% (n=205) vs 2.9% (n=209) placebo @ 26wk15 mg
NCT02033889 · Phase 3
14.6% (n=205) vs 11% (n=209) placebo @ 52wk15 mg
NCT02033889 · Phase 3
12.2% (n=205) vs 7.2% (n=209) placebo @ 104wk15 mg
NCT02033889 · Phase 3
15.4% (n=169) vs 2.4% (n=167) placebo @ 26wk15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
9% (n=2544) vs 4.7% (n=2727) placebo @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.4% (n=2363) vs 6.1% (n=2311) placebo @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.2% (n=1570) vs 5.8% (n=1496) placebo @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.9% (n=1592) vs 5.8% (n=1507) placebo @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.1% (n=876) vs 7.5% (n=786) placebo @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.3% (n=526) vs 6.5% (n=478) placebo @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.7% (n=207) vs 2.9% (n=209) placebo @ 26wk5 mg
NCT02033889 · Phase 3
10.6% (n=207) vs 11% (n=209) placebo @ 52wk5 mg
NCT02033889 · Phase 3
10.6% (n=207) vs 7.2% (n=209) placebo @ 104wk5 mg
NCT02033889 · Phase 3
14.7% (n=170) vs 2.4% (n=167) placebo @ 26wk5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
20.4% (n=49) vs 6.7% (n=45) placebo @ 12wk5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
14.9% (n=47) vs 6.7% (n=45) placebo @ 12wk25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
13.6% (n=44) vs 6.7% (n=45) placebo @ 12wk10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
12% (n=50) vs 6.7% (n=45) placebo @ 12wk1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
Seated DBP -1.08 vs -0.12 placebo mmHg @ 18wk15 mg
absolute change · mmHg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 32 more results
-0.95 vs -0.15 placebo mmHg @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.9 vs -0.23 placebo mmHg @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.92 vs -0.22 placebo mmHg @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.42 vs -0.64 placebo mmHg @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.43 vs -1.26 placebo mmHg @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.86 vs 7.29 placebo mmHg @ 312wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.64 vs -0.26 placebo mmHg @ 18wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.93 vs -2.91 placebo mmHg @ 18wk15 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.92 vs -0.24 placebo mmHg @ 18wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.1 vs -0.72 placebo mmHg @ 26wk15 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.19 vs 0.23 placebo mmHg @ 26wk15 mg
NCT02033889 · Phase 3
-1.19 vs 0.38 placebo mmHg @ 52wk15 mg
NCT02033889 · Phase 3
-1.52 vs -0.46 placebo mmHg @ 104wk15 mg
NCT02033889 · Phase 3
-2.36 vs -0.96 placebo mmHg @ 26wk15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
-0.99 vs -0.12 placebo mmHg @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.97 vs -0.15 placebo mmHg @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.94 vs -0.23 placebo mmHg @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.27 vs -0.22 placebo mmHg @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.45 vs -0.64 placebo mmHg @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.82 vs -1.26 placebo mmHg @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.18 vs 7.29 placebo mmHg @ 312wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.86 vs -0.26 placebo mmHg @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.18 vs -2.91 placebo mmHg @ 18wk5 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.3 vs -0.24 placebo mmHg @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.52 vs -0.72 placebo mmHg @ 26wk5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.59 vs 0.23 placebo mmHg @ 26wk5 mg
NCT02033889 · Phase 3
-1.4 vs 0.38 placebo mmHg @ 52wk5 mg
NCT02033889 · Phase 3
-2.36 vs -0.46 placebo mmHg @ 104wk5 mg
NCT02033889 · Phase 3
-2.38 vs -0.96 placebo mmHg @ 26wk5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
-0.75 vs 0.3 placebo mmHg @ 4wk5 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
-2.71 vs 0.3 placebo mmHg @ 4wk25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
-0.9 vs 0.3 placebo mmHg @ 4wk1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
eGFR -1.81 vs -0.03 placebo mL @ 18wk15 mg
absolute change · mL
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 13 more results
-1.18 vs -0.3 placebo mL @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.35 vs -2.6 placebo mL @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.3 vs -3.8 placebo mL @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.93 vs -4.41 placebo mL @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.9 vs -6.8 placebo mL @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.2 vs -1.8 placebo mL @ 312wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.22 vs -0.03 placebo mL @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.51 vs -0.3 placebo mL @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.48 vs -2.6 placebo mL @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.4 vs -3.8 placebo mL @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.75 vs -4.41 placebo mL @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.4 vs -6.8 placebo mL @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.7 vs -1.8 placebo mL @ 312wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Serum Creatinine Change mg/dL 0.032 vs -0.002 placebo mg/dL @ 18wk15 mg
absolute change · mg/dL
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 13 more results
0.023 vs 0.004 placebo mg/dL @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.035 vs 0.034 placebo mg/dL @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.035 vs 0.049 placebo mg/dL @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.036 vs 0.059 placebo mg/dL @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.042 vs 0.098 placebo mg/dL @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.001 vs -0.013 placebo mg/dL @ 312wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.022 vs -0.002 placebo mg/dL @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.013 vs 0.004 placebo mg/dL @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.024 vs 0.034 placebo mg/dL @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.037 vs 0.049 placebo mg/dL @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.032 vs 0.059 placebo mg/dL @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.027 vs 0.098 placebo mg/dL @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.034 vs -0.013 placebo mg/dL @ 312wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
UACR -14.71% (n=2450) vs 0% (n=2478) placebo @ 18wk15 mg
percent change · % of baseline
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 11 more results
-6.82% (n=2277) vs 5.41% (n=2257) placebo @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.06% (n=2084) vs 17.14% (n=2025) placebo @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.33% (n=1915) vs 27.03% (n=1841) placebo @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
21.25% (n=835) vs 50% (n=745) placebo @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
20% (n=771) vs 48.53% (n=692) placebo @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-13.4% (n=2472) vs 0% (n=2478) placebo @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.53% (n=2306) vs 5.41% (n=2257) placebo @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.73% (n=2125) vs 17.14% (n=2025) placebo @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
13.33% (n=1933) vs 27.03% (n=1841) placebo @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
33.33% (n=825) vs 50% (n=745) placebo @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
30.99% (n=780) vs 48.53% (n=692) placebo @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
PPG 2-hr Change mg/dL -3.47 vs 0.27 placebo mmol/L @ 26wk15 mg
absolute change · mmol/L
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -62.45 mg/dL as posted
show 1 more result
-3.56 vs 0.27 placebo mmol/L @ 26wk*5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -64.15 mg/dL as posted
Glycemic Rescue 1.5% (n=205) vs 17.7% (n=209) placebo @ 26wk15 mg
responder rate · % of participants
NCT02033889 · Phase 3
show 11 more results
1.5% (n=205) vs 17.2% (n=209) placebo @ 52wk15 mg
NCT02033889 · Phase 3
10.7% (n=205) vs 24.4% (n=209) placebo @ 104wk15 mg
NCT02033889 · Phase 3
2% (n=153) vs 16.3% (n=153) placebo @ 26wk15 mg
NCT02036515 · Phase 3
13.7% (n=153) vs 41.8% (n=153) placebo @ 52wk15 mg
NCT02036515 · Phase 3
0.6% (n=169) vs 9.6% (n=167) placebo @ 26wk15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
2.9% (n=207) vs 17.7% (n=209) placebo @ 26wk5 mg
NCT02033889 · Phase 3
4.3% (n=207) vs 17.2% (n=209) placebo @ 52wk5 mg
NCT02033889 · Phase 3
11.1% (n=207) vs 24.4% (n=209) placebo @ 104wk5 mg
NCT02033889 · Phase 3
1.3% (n=156) vs 16.3% (n=153) placebo @ 26wk5 mg
NCT02036515 · Phase 3
12.8% (n=156) vs 41.8% (n=153) placebo @ 52wk5 mg
NCT02036515 · Phase 3
1.2% (n=170) vs 9.6% (n=167) placebo @ 26wk5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
Time to Rescue Therapy 4.57 vs 3.45 placebo months @ 26wk15 mg
time to event · months
NCT02033889 · Phase 3 · converted to months from 139 days as posted
show 1 more result
3.68 vs 3.45 placebo months @ 26wk*5 mg
NCT02033889 · Phase 3 · converted to months from 112 days as posted

+ 23 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapagliflozin's landscape · Ertugliflozin's landscape